Intervet/Schering-Plough Animal Health introduces Nobivac� Lyme, a unique vaccine providing dogs with dual protectionlaunches new canine Lyme vaccine
17 June 2009 Boxmeer (The Netherlands)
ROSELAND, N.J., June 15, 2009 - Intervet/Schering-Plough Animal Health announced the introduction of Nobivac� Lyme. This new-generation Lyme vaccine is the only vaccine specifically designed to provide protection by targeting two key outer surface proteins involved in the transmission of canine Lyme disease. The vaccine induces the production of highly specific antibodies, called borreliacidal antibodies, that kill Borrelia burgdorferi (the causative agent of Lyme disease) by binding to outer surface proteins (Osp) A and C. The ability of Nobivac� Lyme to stimulate borreliacidal antibodies to both OspA and OspC significantly differentiates this vaccine from other currently available products, which only protect against OspA. The unique dual-action of Nobivac� Lyme provides an additional layer of defense against Lyme disease.
Nobivac Lyme is administered by giving two doses subcutaneously, two to four weeks apart, with an annual booster thereafter. (Data supporting one-year duration of immunity are on file with the U.S. Department of Agriculture.) Safety studies demonstrated virtually no site reactions.
Lyme disease is due to a combination of infection with the spirochete and the dog's immune response to the infection. Borrelia burgdorferi is transmitted to the dog by the bite of an infected tick. Once the tick attaches and starts taking a blood meal, the bacteria multiply in the tick's midgut. The bacteria then migrate to the salivary glands of the tick and enter the dog's skin at the site of attachment.
``This vaccine represents a major advance in the prevention of Lyme disease in dogs because, unlike other Lyme vaccines on the market, it induces OspC borreliacidal antibodies that can kill B. burgdorferi at multiple timepoints during the infection process,'' said Rhonda LaFleur, PhD. Group Leader, Biologicals Research and Development, Intervet/Schering-Plough Animal Health. ``OspA borreliacidal antibodies only kill Borrelia while they are in the tick midgut. OspC borreliacidal antibodies, however, kill spirochetes in the tick midgut, spirochetes that are migrating from the midgut to the tick's salivary glands and spirochetes that are introduced into the dog. Nobivac� Lyme thus provides more comprehensive protection for dogs.''
The clinical signs of disease range from subtle lameness to high fever, swollen lymph nodes, lameness, and loss of appetite. Rarely, a dog infected with Lyme disease can develop severe clinical signs that, if left untreated or treated too late, can result in permanent damage to the heart, kidneys, nervous system and joints, or can even be fatal.
``Prevention of Lyme disease is important not only for compassionate reasons but also because caring for sick dogs is expensive and time-consuming,'' said Christopher Pappas, Jr, DVM, Director Technical Services, Intervet/Schering-Plough Animal Health. ``The new vaccine comes at a time when reported incidences of the tick-borne illness are increasingly common.''
Ticks carrying the Lyme disease-causing bacteria have been found throughout the United States with heavy concentrations in the Northeast, mid-Atlantic, upper Midwest, as well as several areas on the West Coast.
NOBIVAC� is a trademark of Intervet/Schering-Plough Animal Health. This press release contains information on a veterinary product based on national registration dossiers and may refer to a product that is either not available in your country or are marketed under a different tradename. In addition, the safety and efficacy data for a specific product may be different depending on local regulations. For more information contact your local Intervet/Schering-Plough Animal Health representative.
Posts: 1227 | From District of Columbia | Registered: Mar 2009
| IP: Logged |
posted
Sounds allot like the people vaccine that didn't go over to well. They were both (People vaccines) taken off the market, adverse reactions were mentioned as the cause. Those were made from OSPA .
Besides my dog can't sue anyone.
Posts: 789 | From CT, | Registered: Jun 2006
| IP: Logged |
posted
Sounds allot like the people vaccine that didn't go over to well. They were both (People vaccines) taken off the market, adverse reactions were mentioned as the cause. Those were made from OSPA .
Posts: 789 | From CT, | Registered: Jun 2006
| IP: Logged |
Leelee
Frequent Contributor (1K+ posts)
Member # 19112
posted
I may have overlooked this information in the article, but does it say when it will be available?
I have three dogs, two of whom have suffered from Lyme and one also had RMSF. They annually receive the Lyme vaccine that is presently available plus monthly does of Frontline.
Although the current vaccines and preventatives for dogs are fairly good, they aren't good enough. I hope this new vaccine can offer more protection.
-------------------- The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy. Martin Luther King,Jr Posts: 1573 | From Maryland | Registered: Feb 2009
| IP: Logged |
Strange that millions of dollars are being spent to develop Lyme vaccines for animals and humans all for a disease that is "hard to catch and easy to cure."
Godspeed.
Posts: 45 | From upstate NY | Registered: Sep 2007
| IP: Logged |
posted
There is no way I would give this to my dogs! After so many people got sick from the human lyme vaccine I wouldn't trust this. That's my 2 cents!
-------------------- My lyme disease blog: http://lymetimes3.blogspot.com/ One BIG Lyme family! I tested CDC + 10/08 My mom Igenex + 11/08 & My brother Igenex + 4/09, My 2 boys some + & IND bands, clinical diagnosis 3/09 (youngest has Aspergers too) Posts: 470 | From Painesville, Ohio | Registered: Mar 2009
| IP: Logged |
posted
I wouldn't give it to a dog either.
Posts: 462 | From Newnan, GA | Registered: Aug 2004
| IP: Logged |
kam
Honored Contributor (10K+ posts)
Member # 3410
posted
Like the caveman from the Geico Insurance ads...Rosie is not to happy with the comment I wouldn't give it to a dog.
Although I understand what you mean.
She was insulted. Posts: 15927 | From Became too sick to work or do household chores in 2001. | Registered: Dec 2002
| IP: Logged |
Marnie
Frequent Contributor (5K+ posts)
Member # 773
posted
Which STRAINS of Bb is this vaccine going to protect against?
All?
I highly doubt it.
What about all of Bb's OTHER Osps (outer surface proteins) which it can express at will when conditions "change"?
"Recombinant antigens of outer surface proteins (Osps) OspA, OspB, OspC, OspE, and OspF of Borrelia burgdorferi sensu stricto
and of p41-G,
an antigenic region of flagellin of this spirochete, were tested with human sera in class-specific and polyvalent enzyme-linked immunosorbent assays (ELISAs)."
Is having antibodies already present to impact Osp A and Osp C (produced in response to a vaccine) going to be enough?
What about the outer surface proteins OspB, OspE, OspF and flagellin?
How is our body gonna handle THOSE antigens (proteins)?
"Preliminary trials in animal models show that treating mice with OspF as a recombinant nonlipidated fusion protein greatly reduces the number of spirochetes (by 90%) within ticks feeding on the mice.
Similarly, a fusion protein of OspE destroyed 75% of the spirochetes in fed ticks.
A chimeric vaccine composed of
combinations of OspA, OspB, OspC, and other protein antigens have been developed,
demonstrating the possibility of a multivalent vaccine against B. burgdorferi ."
OspA and OspC are outer surface proteins that Bb expresses at different times, but what about these:
"We report the cloning and characterization of two outer surface proteins (Osps), designated OspE and OspF, from strain N40 of Borrelia burgdorferi, the spirochetal agent of Lyme disease."
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
![[bow]](graemlins/bow.gif)
![[Big Grin]](biggrin.gif)
Printer-friendly view of this topic